Search Documents and Resources

    • Mission and Vision
    • Board & Staff
    • Financials
    • Contact Us
    • Privacy Policy
    • Donor Privacy Policy
    • Explore our work
    • Center for Defense Information
    • The Constitution Project
    • Congressional Oversight Initiative
    • Policy Letters
    • Reports
    • Testimony
    • For Oversight Staff
    • Whistleblower Resources
    • Report Corruption
  • Take Action
  • Sign Up
  • Donate
  • facebook
  • twitter
  • instagram
  • youtube
    • Mission and Vision
    • Board & Staff
    • Financials
    • Contact Us
    • Privacy Policy
    • Donor Privacy Policy
    • Explore our work
    • Center for Defense Information
    • The Constitution Project
    • Congressional Oversight Initiative
    • Policy Letters
    • Reports
    • Testimony
    • For Oversight Staff
    • Whistleblower Resources
    • Report Corruption
Project On Government Oversight
  • Take Action
  • Sign Up
  • Donate
  • Afghanistan
  • More Topics
  • About
  • Mission & History
  • Board & Staff
  • Financials
  • Take Action
  • For Federal Employees
  • COVID-19: Tips
  • Contact Us
  • Privacy Policy
  • Subscribe
  • Donate
Project On Government Oversight
    • Mission and Vision
    • Board & Staff
    • Financials
    • Contact Us
    • Privacy Policy
    • Donor Privacy Policy
    • Explore our work
    • Center for Defense Information
    • The Constitution Project
    • Congressional Oversight Initiative
    • Policy Letters
    • Reports
    • Testimony
    • For Oversight Staff
    • Whistleblower Resources
    • Report Corruption
  • Take Action
  • Sign Up
  • Donate
Oversight

POGO and Groups Support Better Information on Clinical Trials

By POGO Staff | Filed under letter | May 23, 2012

The Honorable Charles Grassley

United States Senate, Hart 135

Washington, DC 20510

Dear Senator Grassley,

Our undersigned groups strongly support the Grassley Amendment 2129 to S. 3187, the Food and Drug Administration Safety and Innovation Act. Complete and timely reporting of clinical trial results is crucial not only to patients and their doctors, but also to the future of drug innovation in this country.

The Food and Drug Administration Amendments Act of 2007 established clinicaltrials.gov, a groundbreaking reform that has helped thousands of doctors and patients learn more about clinical trials. But clinicaltrials.gov remains a work in progress, with many information gaps. The Grassley amendment would ensure that the work on clinical trial disclosure begun five years ago in FDAAA is fully implemented and meaningful for both patients, clinicians and the pharmaceutical industry.

It would set a deadline for the National Institutes of Health to finalize regulations governing the disclosure of clinical trial data. And it would ask the Government Accountability Office to evaluate how well that data is being reported, with particular attention to any differences between domestic and foreign data.

Since about 80 percent of clinical trials are conducted outside the U.S., and since the F.D.A. inspects less than 1 percent of all foreign clinical trial sites, and less than 2 percent of all domestic sites, it is crucial that we have better information about the completeness and accuracy of clinical trial data.

Better and more complete data also would encourage innovation and save industry resources by informing companies about clinical trials that were stopped because they caused harm or demonstrated lack of efficacy. This would prevent another company contemplating the same pharmaceutical approach from wasting precious research and development dollars. It would also save prospective patients from harm or, at the very least, false hopes about an effective treatment.

We strongly urge your support for this amendment.

Consumers Union

Consumer Federation of America

National Research Center for Women & Families

National Women’s Health Network

Project On Government Oversight (POGO)

Public Citizen

Union of Concerned Scientists

U.S. PIRG

For more information, please contact Paul Brown at the National Research Center for Women & Families at (202) 223-4000 or [email protected]

Author

  • Author

    POGO Staff

Related Tags

    Oversight Public Health Science Accountability Food and Drug Administration (FDA) Transparency

Related Content

Site Footer

  • facebook
  • twitter
  • instagram
  • youtube
  • Press Center
  • Contact Us
  • Careers
  • Briefing
  • Newsletters
  • Publications
  • Report Corruption
Better Business Bureau Accredited Charity CharityWatch Top Rated Charity Great Nonprofits 2021 Top-Rated Charity Navigator Four-Star Charity

©2023 POGO | Privacy Policy

Project On Government Oversight logo

Project On Government Oversight

Oversight in your inbox.